JAMA meta-analysis provokes CV fears with Spiriva
This article was originally published in Scrip
Executive Summary
The most commonly prescribed drugs to treat chronic obstructive pulmonary disease (COPD) -Boehringer Ingelheim/Pfizer's Spiriva (tiotropium bromide) and Boehringer Ingelheim's Atrovent (ipratropium bromide) - have been associated with a significantly increased risk of heart attack, stroke or cardiovascular death, according to a meta-analysis published in the September 24th issue of JAMA.